During the past decade, St. Elisabeth-Krankenhaus conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Elisabeth-Krankenhaus" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "AGO Research GmbH" with 1 trials sponsored, "AIO-Studien-gGmbH" with 1 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored and "Arcagy Research" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Elisabeth-Krankenhaus" #1 collaborator was "German Breast Group" with 3 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologishe Onkologie Germany" with 1 trials as a collaborator and "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "St. Elisabeth-Krankenhaus" are "Breast Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Estrogen Receptor Positive Breast Cancer" (1 trials), "HER-2 Positive Breast Cancer" (1 trials) and "Locally Advanced Pancreatic Cancer" (1 trials). Many other conditions were trialed in "St. Elisabeth-Krankenhaus" in a lesser frequency.

Most popular intervention types in "St. Elisabeth-Krankenhaus" are "Drug" (9 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Fulvestrant" (2 trials), "Placebo" (2 trials), "trastuzumab" (2 trials) and "Anastrozole" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Elisabeth-Krankenhaus" are 5 trials for "Female" genders and 4 trials for "All" genders.

Currently, there are NaN active trials in "St. Elisabeth-Krankenhaus". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in St. Elisabeth-Krankenhaus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in St. Elisabeth-Krankenhaus, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".